Sentences with phrase «of estrogen therapy»

Benefits of Estrogen Therapy: How Can You Benefit?

When you understand the role of estrogen in the body, the benefits of estrogen therapy become clear.

For a comprehensive look at the benefits of estrogen therapy, check out this article.

To measure the effect of estrogen therapy on working memory under stress, Ycaza Herrera recruited 42 women with an average age of 66 from the USC Early versus Late Intervention Trial with Estradiol led by Howard Hodis, a professor at the Keck School of Medicine of USC and a coauthor of the new study.

Half of the postmenopausal women had been on estradiol, a type of estrogen therapy, for approximately five years, while the others had received a placebo.

«This study provides a foundation for future studies to evaluate the value of psycho - social interventions, such as cognitive therapies, to lessen the effect of major life events, as well as the use of estrogen therapy during perimenopausal and menopausal stressful times.»

Previous studies of postmenopausal women have suggested the beneficial effect of estrogen therapy on muscle mass and function.

«Preclinical studies suggest a possible benefit of estrogen therapy when combined with exercise to increase strength and performance and to prevent the loss of muscle mass, but the role of estrogen in muscle mass is not yet clear for postmenopausal women,» says Dr. JoAnn Pinkerton, executive director of NAMS.

Not exact matches

Estrogen Therapy covers a mirade of reproductive health issues for women NOT JUST BIRTH CONTROL.

He was writing in the wake of new revelations about estrogen replacement therapy that showed that the benefits of estrogen had been vastly overstated.

(Progesterone is added to hormone therapy to protect the uterus lining from a risk of cancer seen with estrogen alone.)

Recently, Manson and colleagues published a long - term study of the risk of death in women in the two WHI hormone therapy trials — combined therapy and estrogen alone — from the time of trial enrollment in the mid-1990s until the end of 2014.

In 2004, researchers published results of the WHI study of estrogen - only therapy, taken for about seven years by women who had had their uteruses surgically removed.

However, along with this seemingly linear storyline in which retinoids block progesterone's promotion of CK5 + cells, previous work in the lab of CU Cancer Center investigator Peter Kabos, MD, and others shows that breast cancers treated with anti-estrogen drugs like tamoxifen or aromatase inhibitors show an increased population of CK5 + cells — it is as if these therapies remove the roadblock of estrogen - dependent cells, leaving CK5 + cells to proliferate.

In other words, unfortunately, anti-estrogen therapies may kill estrogen - dependent cells but at the expense of spurring the growth of CK5 + cells.

By replacing the natural estrogen lost during menopause, hormone replacement therapy could be one way for women to regain the cardiovascular benefits of estrogen, Arnson said.

However, other research has suggested that the estrogen - like effects of isoflavones may reduce the effectiveness of endocrine therapies used to treat breast cancer.

Estrogens have been reported to exert protective vascular effects in animal and observational but randomized clinical trials did not report such effects in older women, even suggesting the possibility of an increased CVD risk in this setting, especially with combined estrogen plus progestin therapy.

Hormone replacement therapy (HRT) is a system of medical treatment for perimenopausal and postmenopausal women, based on the assumption that it may prevent discomfort and health problems caused by diminished circulating estrogen hormones.

In 2001 the trend reversed: Breast cancer rates initially dipped gradually, but dropped sharply in mid-2002, when many women in the U.S. stopped hormone replacement therapy after the Women's Health Initiative, a large clinical trial involving estrogen - progestin therapy, was stopped after it was determined that the risks — most notably the increased likelihood of developing breast cancer — outweighed the benefits.

The U.S. study testing the long - term benefits and risks of hormone replacement therapy (HRT) was halted after an interim analysis found that the drugs — a combination of estrogen and progestin — increased the risk of breast cancer, stroke, and heart disease, and that those risks outweighed reduced risks of colorectal cancer and bone fractures (ScienceNOW, 9 July).

«Although oral estrogens are effective for managing menopause symptoms, not enough is known about the cardiovascular safety of different oral hormone therapy products relative to each other,» said first author Nicholas L. Smith, PhD.

Researchers at the Kaiser Permanente Center for Health Research in Portland, Ore., concluded there is definitely a link between breast cancer and the use of menopausal hormone therapy, particularly estrogen - progestin treatment combinations.

Since the report that it did cause breast cancer and many women have stopped taking hormone replacement therapy, we've seen a decrease in breast - cancer incidence, exactly what you'd predict for our understanding of how estrogens work.

Estrogen therapy reduced some of the risk in women who had undergone the procedure.

The drop in hormone use dates back to July 2002, when the Women's Health Initiative, a 15 - year study tracking the health of more than 160,000 women, abruptly ended its long - term study of estrogen - progestin hormone replacement therapy because women taking the drugs faced an elevated risk of invasive breast cancer and heart disease.

«This could be very applicable for women suffering from hot flashes or depression for whom estrogen therapy is really counter-indicated,» says neuropharmacologist Roberta Brinton of the University of Southern California in Los Angeles, who was not involved in the new work.

A breast cancer therapy that blocks estrogen synthesis to activate cancer - killing genes sometimes loses its effectiveness because the cancer takes over epigenetic mechanisms, including permanent DNA modifications in the patient's tumor, once again allowing tumor growth, according to an international team headed by the University of Pittsburgh Cancer Institute (UPCI).

By supplying the correct amounts of estrogen and progesterone via hormone therapy, it is relatively easy to make the uterus of a postmenopausal woman hospitable to a fetus.

Hormonal therapy for patients with estrogen - or progesterone - positive breast cancers can reduce the risk of cancer recurrence by as much as 50 percent.

Perhaps shedding light on this mystery, the researchers found three different types of mutations in the estrogen receptor in patients whose cancer was resistant to anti-hormone therapy.

Currently, there are no molecularly targeted therapies aimed at triple - negative breast cancer, which is a type of cancer negative for estrogen receptor, progesterone receptor and the HER2 protein — all key targets for current therapies.

Prior to the WHI, the accepted view among physicians was that estrogen therapy reduced a woman's risk of developing cognitive impairment.

In June researchers from the Women's Health Initiative Memory Study added a dismal confirmation: estrogen - only replacement therapy in postmenopausal women who've had a hysterectomy not only fails to prevent memory loss but may also increase the risk of dementia.

It is normally very sensitive to estrogen - targeting therapies because of high expression of the estrogen receptor protein, but rarely shows high expression of the HER2 protein.

TNBC is deadly because, unlike other types of breast cancers such as estrogen receptor (ER) positive or HER2 amplified breast tumours which have effective targeted therapy, TNBC tumours do not respond to targeted therapy.

Gwendolyn Thomas, assistant professor of exercise science, is the co-author of a groundbreaking article in the Obesity Journal (The Obesity Society, 2017) about the effects of exercise and physical activity on postmenopausal breast cancer survivors taking AIs — hormone - therapy drugs that stop the production of estrogen.

Because of their dependence on estrogen, these tumors are often treated by estrogen deprivation therapy.

Potential cardioprotection was based on generally supportive data on lipid levels in intermediate outcome clinical trials, trials in nonhuman primates, and a large body of observational studies suggesting a 40 % to 50 % reduction in risk among users of either estrogen alone or, less frequently, combined estrogen and progestin.2 - 5 Hip fracture was designated as a secondary outcome, supported by observational data as well as clinical trials showing benefit for bone mineral density.6, 7 Invasive breast cancer was designated as a primary adverse outcome based on observational data.3, 8 Additional clinical outcomes chosen as secondary outcomes that may plausibly be affected by hormone therapy include other cardiovascular diseases; endometrial, colorectal, and other cancers; and other fractures.3, 6,9

Now, all breast cancers are classified as estrogen - receptor positive or negative, an important guide to prognosis and therapy, and medications, such as tamoxifen, that can block the effects of estrogen have become important tools in the treatment and possible prevention of breast cancer.

Despite marked advances in breast cancer therapy, basal - like breast cancer (BBC), an aggressive subtype of breast cancer usually lacking estrogen and progesterone receptors, remains difficult to treat.

These results, also presented at the 2015 European Cancer Congress (ECC2015, abstract # 5BA) today, which involve the group of 1,626 patients with a Recurrence Score between 0 and 10, demonstrated that 99.3 percent of node - negative, estrogen receptor (ER)- positive, human epidermal growth factor receptor 2 (HER2)- negative patients who met accepted guidelines for recommending chemotherapy in addition to hormonal therapy, had no distant recurrence at five years after treatment with hormonal therapy alone.

«In the Womens Health Initiative (WHI) trial, when women got seven years of estrogen alone, there was no increased risk of breast cancer, but after four to five years on combined hormone therapy, the risk emerges,» she says.

Low doses of prescription medications, including antidepressants, can help relieve hot flashes in overweight women who need immediate relief, Dr. Nachtigall says, as can hormone therapy, which replaces estrogen and other hormones that decline during menopause.

While long - term use of traditional hormone replacement therapies, which include estrogen and progestin, are no longer recommended due to the heart and health risks, there are other options.

Of course, not all women dealing with menopause want to get an estrogen therapy prescription.

If your body has stopped producing a normal amount of testosterone, estrogen, or progesterone, hormone replacement therapy may be the only recourse.

It is not synthetic (the negative press of 20 years ago regarding HRT therapy had to do with synthetic hormones — primarily estrogen — and not growth hormone), and should never be confused with synthetic steroids.

Estrogen therapy works to restore a healthy supply of estrogen to tEstrogen therapy works to restore a healthy supply of estrogen to testrogen to the body.

There are many benefits of natural estrogen replacement therapy.